Compugen Ltd. (NASDAQ:CGEN) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a note issued to investors on Friday.

According to Zacks, “Compugen Ltd. is a pioneer in the fields of computational genomics and proteomics. The company combines the disciplines of mathematics and computer science with molecular biology to improve the understanding of genomics and proteomics, the study of genes and proteins. Compugen’s expertise in these areas is used to develop core technologies and platforms that are the basis for its products and services. These products and services are designed to enable life scientists to significantly enhance their research efforts in drug discovery. “

Separately, FBR & Co set a $14.00 target price on shares of Compugen and gave the stock a “buy” rating in a research note on Friday, May 19th.

Compugen (NASDAQ CGEN) traded down 1.39% during mid-day trading on Friday, reaching $3.55. 125,201 shares of the company were exchanged. Compugen has a 1-year low of $3.25 and a 1-year high of $7.57. The firm’s market capitalization is $181.52 million. The stock has a 50-day moving average of $3.79 and a 200 day moving average of $4.24.

Compugen (NASDAQ:CGEN) last released its earnings results on Wednesday, August 2nd. The biotechnology company reported ($0.18) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.17) by $0.01. Compugen had a negative return on equity of 57.69% and a negative net margin of 4,425.00%. Equities research analysts forecast that Compugen will post ($0.73) earnings per share for the current year.

ILLEGAL ACTIVITY NOTICE: “Compugen Ltd. (CGEN) Stock Rating Lowered by Zacks Investment Research” was first reported by Daily Political and is the property of of Daily Political. If you are accessing this piece of content on another site, it was illegally stolen and reposted in violation of United States & international trademark & copyright legislation. The original version of this piece of content can be read at https://www.dailypolitical.com/2017/08/07/compugen-ltd-cgen-stock-rating-lowered-by-zacks-investment-research.html.

A number of institutional investors have recently made changes to their positions in CGEN. Renaissance Technologies LLC increased its position in shares of Compugen by 15.6% in the fourth quarter. Renaissance Technologies LLC now owns 534,900 shares of the biotechnology company’s stock worth $2,728,000 after buying an additional 72,075 shares during the period. Tower Research Capital LLC TRC increased its position in shares of Compugen by 522.2% in the first quarter. Tower Research Capital LLC TRC now owns 23,576 shares of the biotechnology company’s stock worth $101,000 after buying an additional 19,787 shares during the period. Norges Bank acquired a new position in shares of Compugen during the fourth quarter worth about $658,000. Raging Capital Management LLC increased its position in shares of Compugen by 35.3% in the first quarter. Raging Capital Management LLC now owns 4,236,522 shares of the biotechnology company’s stock worth $18,217,000 after buying an additional 1,104,391 shares during the period. Finally, Vident Investment Advisory LLC increased its position in shares of Compugen by 20.0% in the first quarter. Vident Investment Advisory LLC now owns 150,614 shares of the biotechnology company’s stock worth $648,000 after buying an additional 25,100 shares during the period. 19.37% of the stock is owned by hedge funds and other institutional investors.

About Compugen

Compugen Ltd. is a therapeutic discovery company. The Company focuses on infrastructure to discover drug targets and develop therapeutics. The Company is engaged in the research, development and commercialization of therapeutic and product candidates. The Company’s pipeline primarily consists of early and preclinical stage immuno-oncology programs based on drug targets discovered by the Company, primarily immune checkpoint and myeloid protein target candidates.

Receive News & Ratings for Compugen Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Compugen Ltd. and related companies with MarketBeat.com's FREE daily email newsletter.